I did not want to spend time anymore on the following COVID-19's exact development after obsessing over the outbreak, and potential implications, since the end of January. Well, that didn't work out.
Increasingly, I get the sense that I need to stay up to date on developments because these are informing government/central bank actions, psychology and have a huge practical impact on many businesses.
Because I've been closely following Gilead (GILD) and the remdesivir story (first FDA-approved treatment for COVID-19), recommending it publicly for the first time on February 17, I'm sometimes surprised